Objective: We investigated whether levels of annexin A5,evidence for resistance to annexin A5 activity, and levels antiannexin A5 antibodies might be altered in women with a history of recurrent spontaneous pregnancy ...Objective: We investigated whether levels of annexin A5,evidence for resistance to annexin A5 activity, and levels antiannexin A5 antibodies might be altered in women with a history of recurrent spontaneous pregnancy losses. Study design: These annexin A5 parameters were assayed in 70 nonpregnant women with a history of ≥3 recurrent spontaneous pregnancy losses (cases) and 50 women without adverse pregnancy history (control subjects). Results: Cases had significantly lower plasma annexin A5 levels than control subjects (median, 4.7 ng/mL [range, 0.3-40.4 ng/mL] vs 6.7 ng/mL [range, 0.7-56.0]; P = .01), significantly reduced anticoagulant ratios (188%[range, 119%-279%] vs 238%[range, 159%-286%]; P < .0001), and reduced binding of annexin A5 to phospholipid (6.3 ng/aliquot phospholipid [range, 1.5-16.4 ng/aliquot phospholipid] vs 9.7 ng/aliquot phospholipid (range, 3.5-17.0 ng/aliquot phospholipid]; P = .0002). There were no significant differences in anti-annexin A5 antibody levels. Conclusion: Reduction of annexin A5 and interference with its anticoagulant and binding activities are associated significantly with a history of recurrent spontaneous pregnancy losses. These data support the concept of a significant role for annexin A5 in the maintenance of pregnancy.展开更多
Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a...Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks gestation and annexin A5 (AnxA5) levels were determined with enzyme linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results:AF- AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF- AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF- AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR(P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF- AnxA5 may be a useful marker for identifying pregnancy abnormalities.展开更多
文摘Objective: We investigated whether levels of annexin A5,evidence for resistance to annexin A5 activity, and levels antiannexin A5 antibodies might be altered in women with a history of recurrent spontaneous pregnancy losses. Study design: These annexin A5 parameters were assayed in 70 nonpregnant women with a history of ≥3 recurrent spontaneous pregnancy losses (cases) and 50 women without adverse pregnancy history (control subjects). Results: Cases had significantly lower plasma annexin A5 levels than control subjects (median, 4.7 ng/mL [range, 0.3-40.4 ng/mL] vs 6.7 ng/mL [range, 0.7-56.0]; P = .01), significantly reduced anticoagulant ratios (188%[range, 119%-279%] vs 238%[range, 159%-286%]; P < .0001), and reduced binding of annexin A5 to phospholipid (6.3 ng/aliquot phospholipid [range, 1.5-16.4 ng/aliquot phospholipid] vs 9.7 ng/aliquot phospholipid (range, 3.5-17.0 ng/aliquot phospholipid]; P = .0002). There were no significant differences in anti-annexin A5 antibody levels. Conclusion: Reduction of annexin A5 and interference with its anticoagulant and binding activities are associated significantly with a history of recurrent spontaneous pregnancy losses. These data support the concept of a significant role for annexin A5 in the maintenance of pregnancy.
文摘Objective: The purpose of this study was to determine whether amniotic fluid levels of annexinA5 (AF- AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design:Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks gestation and annexin A5 (AnxA5) levels were determined with enzyme linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results:AF- AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF- AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF- AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR(P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF- AnxA5 may be a useful marker for identifying pregnancy abnormalities.
